

## MultiCASE CASE Ultra model for cytochrome P450 isoenzyme 2D6 (CYP2D6) substrates (human clinical data)

### 1. QSAR identifier

#### 1.1 QSAR identifier (title)

MultiCASE CASE Ultra model for cytochrome P450 isoenzyme 2D6 (CYP2D6) substrates (human clinical data), Danish QSAR Group at DTU Food.

#### 1.2 Other related models

Leadscope Enterprise model for cytochrome P450 isoenzyme 2D6 (CYP2D6) substrates (human clinical data), Danish QSAR Group at DTU Food.

SciMatics SciQSAR model for cytochrome P450 isoenzyme 2D6 (CYP2D6) substrates (human clinical data), Danish QSAR Group at DTU Food.

#### 1.3. Software coding the model

MultiCASE CASE Ultra 1.4.6.6 64-bit.

## 2. General information

### 2.1 Date of QMRF

January 2015.

### 2.2 QMRF author(s) and contact details

QSAR Group at DTU Food;

Danish National Food Institute at the Technical University of Denmark;

<http://qsar.food.dtu.dk/>;

qsar@food.dtu.dk

Sine Abildgaard Rosenberg;

National Food Institute at the Technical University of Denmark;

Trine Klein Reffstrup;

National Food Institute at the Technical University of Denmark;

Eva Bay Wedebye;

National Food Institute at the Technical University of Denmark;

Nikolai Georgiev Nikolov;

National Food Institute at the Technical University of Denmark;

Marianne Dybdahl;

National Food Institute at the Technical University of Denmark.

### 2.3 Date of QMRF update(s)

### 2.4 QMRF update(s)

## 2.5 Model developer(s) and contact details

Tine Ringsted;

National Food Institute at the Technical University of Denmark;

Jay Russel Niemelä;

National Food Institute at the Technical University of Denmark;

Svava Ósk Jónsdóttir;

National Food Institute at the Technical University of Denmark;

Nikolai Georgiev Nikolov;

National Food Institute at the Technical University of Denmark;

Eva Bay Wedebye;

National Food Institute at the Technical University of Denmark;

Danish QSAR Group at DTU Food;

National Food Institute at the Technical University of Denmark;

[http://qsar.food.dtu.dk/;](http://qsar.food.dtu.dk/)

[qsar@food.dtu.dk](mailto:qsar@food.dtu.dk)

## 2.6 Date of model development and/or publication

January 2014.

## 2.7 Reference(s) to main scientific papers and/or software package

Klopman, G. (1992) MULTICASE 1. A Hierarchical Computer Automated Structure Evaluation Program. *Quant. Struct.-Act. Relat.*, 11, 176 - 184.

Chakravarti, S.K., Saiakhov, R.D., and Klopman, G. (2012) Optimizing Predictive Performance of CASE Ultra Expert System Models Using the Applicability Domains of Individual Toxicity Alerts. *J. Chem. Inf. Model.*, 52, 2609 -2618.

Saiakhov, R.D., Chakravarti, S.K., and Klopman, G. (2013) Effectiveness of CASE Ultra Expert System in Evaluating Adverse Effects of Drugs. *Mol. Inf.*, 32, 87 – 97.

#### 2.8 Availability of information about the model

The training set is non-proprietary and was compiled from the published literature (see 6.5 for more details). The model algorithm is proprietary from commercial software.

#### 2.9 Availability of another QMRF for exactly the same model

### 3. Defining the endpoint

#### 3.1 Species

Human (primarily clinical data).

#### 3.2 Endpoint

QMRF 5. Toxicokinetics

QMRF 5. 8. Toxicokinetics. Metabolism (including metabolic clearance)

#### 3.3 Comment on endpoint

The cytochrome P450 (CYP) superfamily of heme-containing enzymes plays a significant role in phase I metabolism of a wide range of endogenous compounds and xenobiotics. It is therefore an important factor in drug development and drug therapy to determine if a drug is metabolized by CYP enzymes. Beside drugs, CYP enzymes detoxify environmental compounds and chemicals in consumer products. They also have the ability to form reactive intermediates that can damage DNA, lipids and proteins, and potentially lead to tumor initiation and cancer after long term exposure. The human genome encodes 57 different CYP genes, with five of these enzymes being responsible for the metabolism of 95% of drugs, namely CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. The modulation of CYP activity by inhibition or induction of drugs or other chemicals can cause problems ranging from insufficient therapeutic effect to fatal toxic consequences.

The isoenzyme CYP2D6 is primarily expressed in the liver and the mucosa of the small intestine and is considered to be involved in the metabolism of 12–15% of prescribed drugs including antidepressants, antipsychotics, some antiarrhythmics, beta-blockers and analgesics. CYP2D6 is associated with substantial genetic polymorphism causing large inter-individual differences in enzyme activity, and the difference in CYP2D6 activity makes some people more vulnerable to CYP2D6 substrates because of inadequate excretion (poor metaboliser (PM)) or rapid excretion (ultrarapid metaboliser (UM)) of drugs. CYP2D6 also has the possibility of forming harmful intermediates.

The metabolism activity of CYP2D6 is, in many cases, facilitated by an ion pair interaction between an aspartic acid residue at the active site and a protonated nitrogen atom of the substrate. Substrates of CYP2D6 contain a basic nitrogen atom 5Å or 7Å from the point of oxidation with aromatic rings positioned coplanar in the substrate.

Data for this model is based on human clinical data for CYP2D6, primarily drugs, gathered from the literature.

#### 3.4 Endpoint units

CASE units, 45 for positives and 10 for negatives.

#### 3.5 Dependent variable

Human cytochrome P450 isoenzyme 2D6 (CYP2D6), substrates or non-substrates.

### 3.6 Experimental protocol

Data were either obtained from *in vivo* clinical experiments or various *in vitro* models like tissues slices, microsomes, cell cultures and purified and recombinant enzymes that have formed the basis for a clinical decision. Epidemiological observations and case studies may also have served as input for such decisions.

Since data is obtained from various sources a common protocol have not been used, please see references in 9.2 for further information on the experimental protocols.

### 3.7 Endpoint data quality and variability

As data for the training set were compiled from multiple sources and no common experimental protocol has been described a certain degree of variability in data exists. In addition to this the main part of the training set consist of human clinical data and this type of data is associated with a high degree of variability because of the many factors affecting humans, such as genetics, lifestyle etc.

## 4. Defining the algorithm

### 4.1 Type of model

A categorical (Q)SAR model based on structural fragments and calculated molecular descriptors.

### 4.2 Explicit algorithm

This is a categorical (Q)SAR model composed of multiple local (Q)SARs made by use of stepwise regression. The specific implementation is proprietary within the MultiCASE CASE Ultra software.

### 4.3 Descriptors in the model

Fragment descriptors,

Distance descriptors,

Physical descriptors,

Electronic descriptors,

Quantum mechanical descriptors

### 4.4 Descriptor selection

Automated hierarchical selection (see 4.5).

### 4.5 Algorithm and descriptor generation

MultiCASE CASE Ultra is an artificial intelligence (AI) based computer program with the ability to learn from existing data and is the successor to the program MultiCASE MC4PC. The system can handle large and diverse sets of chemical structures to produce so-called global (Q)SAR models, which are in reality series of local (Q)SAR models. Upon prediction of a query structure by a given model one or more of these local models, as well as global relationships if these are identified, can be involved if relevant for the query structure. The CASE Ultra algorithm is mainly built on the MCASE methodology (Klopman 1992) and was released in a first version in 2011 (Chakravarti *et al.* 2012, Saiakhov *et al.* 2013).

CASE Ultra is a fragment-based statistical model system. The methodology involves breaking down the structures of the training set into all possible fragments from 2 to 10 heavy (non-hydrogen) atoms in length. The fragment generation procedure produces simple linear chains of varying lengths and branched fragments as well as complex substructures generated by combining the simple fragments.

A structural fragment is considered as a positive alert if it has a statistically significant association with chemicals in the active category. It is considered a deactivating alert if it has a statistically significant relation with the inactive category.

Once final lists of positive and deactivating alerts are identified, CASE Ultra attempts to build local (Q)SARs for each alert in order to explain the variation in activity within the training set chemicals covered by that alert. The program calculates multiple molecular descriptors from the chemical structure such as molecular orbital energies and two-dimensional distance descriptors. A stepwise regression method is used to build the local (Q)SARs based on these molecular descriptors. For each step a new descriptor (modulator) is

added if the addition is statistically significant and increases the cross-validated R<sup>2</sup> (the internal performance) of the model. The number of descriptors in each local model is never allowed to exceed one fifth of the number of training set chemicals covered by that alert. If the final regression model for the alert does not satisfy certain criteria ( $R^2 \geq 0.6$  and  $Q^2 \geq 0.5$ ) it is rejected. Therefore, not all alerts will necessarily have a local (Q)SAR.

The collection of positive and deactivating alerts with or without a local (Q)SAR constitutes a global (Q)SAR model for a particular endpoint and can be used for predicting the activity of a test chemical.

More detailed information about the algorithm can be found in Chakravarti *et al.* (2012), Saiakhov *et al.* (2013).

#### 4.6 Software name and version for descriptor generation

MultiCASE CASE Ultra 1.4.6.6 64-bit.

#### 4.7 Descriptors/chemicals ratio

The program primarily uses fragment descriptors specific to a group of structurally related chemicals from the training set. Therefore estimation of the number of descriptors used in a specific model, which is a collection of local models as explained under 4.5, may be difficult. In general, we estimate that the model uses an order of magnitude less descriptors than there are observations. The number of descriptors in each local (Q)SAR model is never allowed to exceed one fifth of the number of training set chemicals covered by that alert (Saiakhov *et al.* 2013).

It should be noted that due to CASE Ultra's complex decision making scheme overfitting is rare compared to simpler linear models. Warnings are issued in case of statistically insufficient overall number of observations to produce a model, which is not the case in the present model.



## 5. Defining Applicability Domain

### 5.1 Description of the applicability domain of the model

The definition of the applicability domain consists of two components; the definition in CASE Ultra and the in-house further refinement algorithm on the output from CASE Ultra to reach the final applicability domain call.

#### 1. CASE Ultra

CASE Ultra recognizes unknown structural fragments in test chemicals that are not found in the training data and lists these in the output for a prediction. Fragments this way impose a type of global applicability domain for the overall model. The presence of more than three unknown structural fragments in the test chemical results in an 'out of domain' call in the program. (Chakravarti *et al.*2012, Saiakhov *et al.*2013).

For each structural alert, CASE Ultra uses the concept of so-called domain adherences and statistical significance.

The domain adherence for an alert in a query chemical depends on the similarity of the chemical space around the alert in the query chemical compared to the chemical space (in terms of frequencies of occurrences of statistically relevant fragments) of the training set chemicals used to derive the alert. The domain adherence value (between zero and one) is the ratio of the sum of the squared frequency of occurrence values of the subset of the fragments that are present in the test chemical and sum of the squared frequency of occurrence of all the fragments that constitute the domain of the alert in question. The more fragments of the domain of the alert in the test chemical the closer the domain adherence value is to 1. The value will never be zero as the alert itself is part of the alerts domain.

Furthermore, all alerts come with a measure of its statistical significance, and this depends on the number of chemicals in the training set which contained the alert and the prevalence within these of actives and inactives. (Chakravarti *et al.*2012).

#### 2. In-house refinement algorithm to reach the final applicability domain call

The Danish QSAR group has applied a stricter definition of applicability domain for its MultiCASE CASE Ultra models.

An optimization procedure based on preliminary cross-validation is applied to further restrict the applicability domain for the whole model based on non-linear requirements for domain adherence and statistical significance, giving the following primary thresholds:

Domain adherence = 0.64 and significance = 70

Any positive prediction is required to contain at least one valid positive alert, namely an alert with statistical significance and domain adherence exceeding thresholds defined for the specific model.

The positive predictions for chemicals which only contain invalid positive alerts are considered 'out of domain' (in CASE Ultra these chemicals are predicted to be inactive).

Furthermore, only query chemicals with no unknown structural fragments are considered within the applicability domain, except for chemicals predicted 'positive', where one unknown fragment is accepted. Also no significant positive alerts are accepted for an inactive prediction.

## 5.2 Method used to assess the applicability domain

The applicability domain is assessed in terms of the output from CASE Ultra with the Danish QSAR group's further refinement algorithm on top as described in 5.1.

Because of the complexity of the system (see 5.1), the assessment of whether a test chemical is within the applicability domain of the model requires predicting the chemical with the specific model, and the application of the Danish QSAR group model-specific thresholds for domain adherence and significance.

This applicability domain was also applied when determining the results from the cross-validations (6.9).

## 5.3 Software name and version for applicability domain assessment

MultiCASE CASE Ultra 1.4.6.6 64-bit.

## 5.4 Limits of applicability

All structures are run through the DataKurator feature within CASE Ultra to check for compatibility with the program. Furthermore, the Danish QSAR group applies an overall definition of structures acceptable for QSAR processing which is applicable for all the in-house QSAR software, i.e. not only CASE Ultra. According to this definition accepted structures are organic substances with an unambiguous structure, i.e. so-called discrete organics defined as: organic compounds with a defined two dimensional (2D) structure containing at least two carbon atoms, only certain atoms (H, Li, B, C, N, O, F, Na, Mg, Si, P, S, Cl, K, Ca, Br, and I), and not mixtures with two or more 'big components' when analyzed for ionic bonds (for a number of small known organic ions assumed not to affect toxicity the 'parent molecule' is accepted). Structures with less than two carbon atoms or containing atoms not in the list above (e.g. heavy metals) are rendered out as not acceptable for further QSAR processing. Calculation 2D structures (SMILES and/or SDF) are generated by stripping off accepted organic and inorganic ions. Thus, all the training set and prediction set chemicals are used in their non-ionized form. See 5.1 for further applicability domain definition.

## 6. Internal validation

### 6.1 Availability of the training set

Yes

### 6.2 Available information for the training set

CAS

SMILES

### 6.3 Data for each descriptor variable for the training set

No

### 6.4 Data for the dependent variable for the training set

All

### 6.5 Other information about the training set

745 compounds are in the training set: 247 substrates and 499 non-substrates.

Data for the training set was compiled from the following sources: Hodgson (2001), Rendric (2002), Skinner *et al.* (2003), Dong (2005), Koumis and Samuel (2005), Yap and Chen (2005), Skerjanic (2006), Peters *et al.* (2007), Urichuk *et al.* (2008), and Draper (2009).

### 6.6 Pre-processing of data before modelling

Only structures acceptable for the commercial software were used in the training set. That is only discrete organic chemicals as described in 5.4 were used. In case of replicate structures, one of the replicates was kept if all the compounds had the same activity and all were removed if they had different activity.

### 6.7 Statistics for goodness-of-fit

### 6.8 Robustness – Statistics obtained by leave-one-out cross-validation

Not performed. (It is not a preferred measurement for evaluating large models).

### 6.9 Robustness – Statistics obtained by leave-many-out cross-validation

A five times two-fold 50 % cross-validation was performed. This was done by randomly removing 50% of the full training set used to make the “mother model”, thereby splitting the full training set into two subsets A and B, each containing the same ratio of positives to negatives as the full training set. A new model (validation sub-model) was created on subset A without using any information from the “mother model” (regarding e.g. descriptor selection etc.). The validation sub-model was applied to predict subset B (within the CASE Ultra applicability domain for the validation sub-model and the in-house further refinement algorithm for the full model). Likewise, a validation sub-model was made on subset B and this model was used to predict subset A (within the CASE Ultra applicability domain for the validation sub-

model and the in-house further refinement algorithm for the full model). This procedure was repeated five times.

Predictions within the defined applicability domain for the ten validation sub-models were pooled and Cooper's statistics calculated. This gave the following results for the 52.8% (1971/(5\*746)) of the predictions which were within the applicability domain:

- Sensitivity (true positives / (true positives + false negatives)): 43.9%
- Specificity (true negatives / (true negatives + false positives)): 87.0%
- Concordance ((true positives + true negatives) / (true positives + true negatives + false positives + false negatives)): 74.1%

6.10 Robustness - Statistics obtained by Y-scrambling

Not performed.

6.11 Robustness - Statistics obtained by bootstrap

Not performed.

6.12 Robustness - Statistics obtained by other methods

Not performed.

## 7. External validation

7.1 Availability of the external validation set

7.2 Available information for the external validation set

7.3 Data for each descriptor variable for the external validation set

7.4 Data for the dependent variable for the external validation set

7.5 Other information about the validation set

7.6 Experimental design of test set

7.7 Predictivity – Statistics obtained by external validation

7.8 Predictivity – Assessment of the external validation set

7.9 Comments on the external validation of the model

External validation has not been performed for this model.

## 8. Mechanistic interpretation

### 8.1 Mechanistic basis of the model

The model identifies statistically relevant substructures (i.e. alerts) and for each set of molecules containing a specific alert it further identifies additional parameters found to modulate the alert (e.g. logP and molecular orbital energies, etc.). Many predictions may indicate modes of action that are obvious for persons with expert knowledge about the endpoint.

### 8.2 A priori or posteriori mechanistic interpretation

A posteriori mechanistic interpretation. The identified structural features and molecular descriptors may provide basis for mechanistic interpretation.

### 8.3 Other information about the mechanistic interpretation

## 9. Miscellaneous information

### 9.1 Comments

The model can be used to predict if a chemical is a substrate of the cytochrome P450 2D6 isoenzyme in humans.

### 9.2 Bibliography

Dong, B.J. (2005) Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. *Clin. Ther.*, 27:4, 1725–1751.

Draper, E. (2009) New drug bulletin: Budesonide and Formoterol (Symbicort-AstraZeneca), University of Utah Hospitals and Clinics, E. Fox, ed., Accessed 12 February 2009, Available at [http://healthcare.utah.edu/pharmacy/bulletins/NDB\\_136.pdf](http://healthcare.utah.edu/pharmacy/bulletins/NDB_136.pdf).

Hodgson, E. (2001) In vitro human phase I metabolism of xenobiotics I: Pesticides and related chemicals used in agriculture and public health, September 2001. *J. Biochem. Mol. Toxicol.*, 15:6, 296–299.

Jónsdóttir, S.Ó., Ringsted, T., Nikolov, N.G., Dybdahl, M., Wedebye, E.B., Niemelä, J.R. (2012). Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis. *Bioorganic & Medicinal Chemistry* 20, 2042–2053.

Koumis, T., and Samuel, S. (2005) Tiotropium bromide: A new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. *Clin. Ther.*, 27:4, 377–392.

Peters F.T., Dragan, C.A., Wilde, D.R., Meyer, M.R., Zapp, J., Bureik, M., and Maurer, H.H. (2007) Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 40-hydroxymethyl-alpha-pyrrolidinobutyrophenone. *Biochem. Pharmacol.*, 74, 511–520.

Rendic, S. (2002) Summary of information on human CYP enzymes: Human P450 metabolism data. *Drug Metabolism Reviews*, 34(1&2), 83–448.

Ringsted, T., Nikolov, N., Jensen, G.E., Wedebye, E.B., and Niemelä, J. (2009) QSAR Models for P-450 (2D6) Substrate Activity. *SAR and QSAR in Environmental Research*, 20:3, 309–325.

Skerjanec, A. (2006) The clinical pharmacokinetics of darifenacin. *Clin. Pharmacokinet.*, 45:4, 325–350.

Skinner, M.H., Kuan, H.Y., Pan, A., Sathirakul, K., Knadler, M.P., Gonzales, C.R., Yeo, K.P. Reddy, S., Lim, M., Ayan-Oshodi, M., and Wise, S.D. (2003) Duloxetine is both an inhibitor and a substrate of cytochrome P450 2D6 in healthy volunteers. *Clin Pharmacol Ther.*, 73:3, 170–177.

Urichuk, L., Prior, T.I., Dursun, S., and Baker, G. (2008) Metabolism of atypical antipsychotics: Involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. *Curr. Drug Metab.*, 9, 410–418.

Yap, C. W., and Chen, Y. Z. (2005) Prediction of Cytochrome P450 3A4, 2D6, and 2C9 Inhibitors and Substrates by Using Support Vector Machines. *J. Chem. Inf. Model*, 45, 982–992.

### 9.3 Supporting information